Free Trial
$100 Off. Every Year. Lock In MarketBeat All Access at $149
Claim the Rate Lock
Claim MarketBeat All Access Sale Promotion
NASDAQ:DNLI

Denali Therapeutics Q3 2026 Earnings Date & Estimates

Denali Therapeutics logo
$18.66 +0.25 (+1.36%)
Closing price 04:00 PM Eastern
Extended Trading
$18.47 -0.19 (-1.04%)
As of 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Denali Therapeutics is estimated to report Q3 2026 earnings on Tuesday, November 3, 2026, after market closes. The conference call is scheduled for 4:30 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call
4:30 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Denali Therapeutics in Q3 2026

Denali Therapeutics is expected to post earnings of -$0.3222 per share on revenue of $12.22 million. In the same quarter a year earlier Denali Therapeutics reported -$0.74 per share. Denali Therapeutics last reported on August 6, 2026, posting -$0.68 per share and missing the -$0.5131 consensus estimate. Denali Therapeutics has beaten the consensus EPS estimate in 5 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.3222
Expected Revenue
$12.22 million
Prior-Year EPS
-$0.74

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.68 (Missed by -$0.1670)
Last Quarter Revenue
$3.60 million
EPS Beat Rate
5 of last 8 quarters

Prepare for the Q3 2026 Call

Denali Therapeutics Q3 2026 Earnings FAQ

Denali Therapeutics (NASDAQ:DNLI) is estimated to report Q3 2026 earnings on Tuesday, November 3, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it.

Denali Therapeutics' Q3 2026 earnings conference call is scheduled for Tuesday, November 3, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Denali Therapeutics to post earnings of -$0.3222 per share for Q3 2026.

The consensus revenue estimate for Denali Therapeutics is $12.22 million for Q3 2026.

Denali Therapeutics Earnings Headlines

Denali Therapeutics (NASDAQ:DNLI) Stock Rating Raised to Hold at Wall Street Zen
October 24 at 1:15 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31151431
Denali Therapeutics to Report Third Quarter 2026 Financial Results and Business Highlights on November 3, 2026
October 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/22/3386869/0/en/denali-therapeutics-to-report-third-quarter-2026-financial-results-and-business-highlights-on-november-3-2026.html
NEVER thought this would happen again
Twenty five years ago, this analyst predicted the fiber optic boom and called Amazon before it became a household name. Now he says a similar shift is unfolding in AI infrastructure. Hundreds of billions are pouring into AI data centers, but he warns the builders could get crushed by their own costs while one overlooked sector absorbs the spending.tc pixel
October 26 at 1:00 AM  |  Porter & Company (Ad)
Denali Therapeutics Inc. (DNLI) - What Are Investment Firms Saying About This Stock?
October 22, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31145191
Can Denali's Brain-Delivery Platform Drive Its Next Phase Of Growth?
October 21, 2026  |  rttnews.comhttps://www.rttnews.com/3701164/can-denali-s-brain-delivery-platform-drive-its-next-phase-of-growth.aspx
Wedbush Cuts Price Target on Denali Therapeutics to $23 From $27, Keeps Outperform Rating
October 19, 2026  |  marketscreener.comM
See More Denali Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Denali Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Denali Therapeutics and other key companies, straight to your email.

About Denali Therapeutics

Denali Therapeutics (NASDAQ:DNLI) is a biopharmaceutical company focused on discovering and developing therapies for patients with neurodegenerative diseases. The company’s research programs target conditions including Parkinson’s disease, Alzheimer’s disease, amyotrophic lateral sclerosis, and lysosomal storage disorders.

Denali uses its blood-brain barrier transport technology, known as the Transport Vehicle platform, to design medicines intended to deliver therapeutic proteins and other biologic treatments into the central nervous system. Its pipeline has included investigational treatments aimed at reducing neurodegenerative disease mechanisms such as impaired protein clearance, neuroinflammation, and cellular stress.

Founded in 2013 and headquartered in South San Francisco, California, Denali conducts research and clinical development activities in collaboration with pharmaceutical and biotechnology companies. The company’s leadership includes co-founder Ryan Watts, who serves as chief executive officer. Its programs are developed for potential use in international markets, subject to clinical results and regulatory approval.

View Denali Therapeutics Profile
Earnings Tools